Alfasigma
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 3 disclosed transactions, Alfasigma concentrates its licensing activity in Gastroenterology, Metabolic. Alfasigma pays a 0.70x discount to market median. Their most common deal structure is Acquisition, with an average disclosed value of $645M. Most recent activity: 2026.
Pipeline coverage & gaps
Alfasigma has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 2 | $622M | $622M |
| License | 1 | $300M | $690M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | linerixibat | GSK | primary biliary cholangitis (PBC) - itching | phase_3 | $300M | $690M |
| 2024 | gerd | Phathom Pharmaceuticals | gerd | approved | $450M | $450M |
| 2023 | Ocaliva (OCA) acquisition | Intercept Pharmaceuticals | PBC (approved), NASH | approved | $794M | $794M |
How this is computed
For each Alfasigma deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.237, clamped to [0.7, 1.5].